Press Releases

Date Title and Summary View
Apr 27, 2017
MacroGenics Announces Registered Direct Offering of Common Stock
Rockville, MD, April 27, 2017 (GLOBE NEWSWIRE) -- --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Apr 26, 2017
MacroGenics to Present at Two Upcoming Investor Conferences in May
Rockville, MD, April 26, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Apr 25, 2017
MacroGenics Announces Date of First Quarter 2017 Financial Results Conference Call
ROCKVILLE, MD , April 25, 2017 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 3, 2017 , the Company will release its financial results for the quarter ended March 31, 2017 . The Company's management team will host a conference call discussing the
Additional Formats
Mar 31, 2017
Eight Posters Based on MacroGenics-developed Molecules Featured at AACR Annual Meeting 2017
Rockville, MD, March 31, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Mar 29, 2017
MacroGenics to Present at the Needham Healthcare Conference
Rockville, MD, March 29, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Feb 28, 2017
MacroGenics Provides Update on Corporate Progress and 2016 Financial Results
ROCKVILLE, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Feb 27, 2017
MacroGenics to Participate in Two Upcoming Investor Conferences
Rockville, MD, Feb. 27, 2017 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Feb 16, 2017
MacroGenics Announces Date of Fourth Quarter and Full Year 2016 Financial Results Conference Call
ROCKVILLE, MD, Feb. 16, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Feb 09, 2017
MacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
ROCKVILLE, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Jan 25, 2017
MacroGenics Announces Appointments to Board of Directors
Rockville, MD , Jan. 25, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Jan 05, 2017
MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA
ROCKVILLE, MD , Jan. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Jan 05, 2017
MacroGenics to Present at the 35th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, MD, Jan. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Dec 13, 2016
MacroGenics Highlights Progress at 2016 R&D Day
Advancement of HER2 franchise led by margetuximab Expansion and progression of B7-H3 franchise Introduction of PD-1 directed immuno-oncology franchise Clinical updates on multiple DART® studies underscore platform progress Pipeline poised to expand with at least 3 new INDs from internal R&D in
Additional Formats
Dec 12, 2016
MacroGenics Licenses Synthon's Technology to Develop an Anti-B7-H3 ADC
ROCKVILLE, Md. and NIJMEGEN, the Netherlands, Dec. 12, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune
Additional Formats
Dec 08, 2016
MacroGenics to Host 2016 R&D Day

Company to provide in-depth review of its antibody-based technology platforms and broad portfolio of therapeutics being developed to treat cancer, autoimmune disorders and infectious diseases

Additional Formats
Nov 02, 2016
MacroGenics Provides Update on Corporate Progress and Third Quarter 2016 Financial Results
Continued expansion and advancement of product candidates Portfolio update planned for upcoming R&D Day on December 13, 2016 ROCKVILLE, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative
Additional Formats
Nov 01, 2016
MacroGenics to Participate in Two Upcoming Investor Conferences
Rockville, MD, Nov. 01, 2016 (GLOBE NEWSWIRE) -- --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Oct 26, 2016
MacroGenics Announces Date of Third Quarter 2016 Financial Results Conference Call
Rockville, MD, Oct. 26, 2016 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 2, 2016, the Company will release its financial results for the quarter ended September 30, 2016. The Company's management team will host a conference call discussing the
Additional Formats
Sep 23, 2016
MacroGenics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Rockville, MD, Sept. 23, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Sep 20, 2016
MacroGenics Announces the Promotion of Three Executives
Rockville, MD, Sept. 20, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Sep 12, 2016
Takeda and MacroGenics Announce the Conclusion of their MGD010 License and Option Agreement

MacroGenics regains worldwide rights to DART molecule for autoimmune disorders

Additional Formats
Aug 31, 2016
MacroGenics to Participate in Two Upcoming Investor Conferences
Rockville, MD, Aug. 31, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Aug 04, 2016
MacroGenics to Participate in Two Upcoming Investor Conferences
Rockville, MD, Aug. 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases,
Additional Formats
Aug 03, 2016
MacroGenics Provides Update on Corporate Progress and Second Quarter 2016 Financial Results
MGD010 Phase 1 clinical DART® data presented at EULAR Entered into collaboration with Janssen to develop MGD015 On track for three new IND submissions in 2016-2017 ROCKVILLE, Md., Aug. 03, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused
Additional Formats
Jul 27, 2016
MacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call
Rockville, MD, July 27, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 3, 2016, the Company will release its financial results for the quarter ended June 30, 2016. The Company's management team will host a conference call discussing the Company's
Additional Formats